论文部分内容阅读
B细胞慢性淋巴细胞性白血病(B-CLL)临床病程长短不一,其预后判断通常依据淋巴浸润、贫血及血小板减少的程度.人们早已认识CLL患者的B细胞携带有特异性IgGFc受体(FCrR),文章着重探讨B-CLL患者FcrR表达的预后意义.63例B-CLL患者,40例尚未接受治疗,23例接受糖皮质激素或细胞毒性药物治疗,获取静脉血标本后,按以往文献报道的方法进行淋巴细胞制备及三种FcrR检测.
The clinical course of B-cell chronic lymphocytic leukemia (B-CLL) varies in length, and its prognosis is usually based on the extent of lymphoid infiltration, anemia, and thrombocytopenia. It has long been known that B cells in CLL patients carry specific IgGFc receptor (FCrR ), The article focuses on the prognostic significance of FcRR expression in B-CLL patients .63 cases of B-CLL patients, 40 patients have not yet received treatment, 23 patients received glucocorticoid or cytotoxic drugs, venous blood samples obtained, according to previous reports Methods for lymphocyte preparation and three FcrR assays.